At the "Venture Capital Day" - The High-Quality Development Conference of the Shenzhen Angel FOF Industry, the event embraced the pivotal theme "Led by Angel Funds, Shielded by Industry", and grandly unfolded on April 8th in Shenzhen’s Futian District. With its commitment to “Led by Angel Funds, Shielded by Industry,” the conference set its sights on forging new pathways for the venture capital sector in Shenzhen. Through rich dialogue and partnerships, it’s poised to propel Shenzhen’s strategic industries, infusing them with the vigor needed for their high-quality evolution. Invited for its expertise, CR Capital stepped up to deliver an insightful keynote address and engaged in a pivotal signing to bolster the "Biopharmaceutical and Healthcare Industries Incubation Program."
Spearheaded by a coalition of eminent bodies including the Guangdong Development and Reform Commission, the Office of the Financial Committee and the Office of the Science & Technology Innovation Committee of Shenzhen Municipal Committee of the CPC, alongside the Industry and Information Technology Bureau of Shenzhen Municipality, the event was a collaborative effort. The Shenzhen Financial Stability & Development Institute, alongside the Shenzhen Angel Investment Guidance Fund Management Co., Ltd., played significant roles in orchestrating the proceedings. Drawing in a vibrant assembly of over a hundred entities, from venture capital firms and industry conglomerates to angel investors and nascent enterprises, the event was a fertile ground for innovation and partnership. Wu Kunsheng, the Deputy Secretary-general of Shenzhen Municipal People’s Government, delivered a speech at the conference.
With a visionary perspective, Qin Feng, General Manager and CEO of CR Capital, took the stage to unravel the intricacies of "Industrial Investment within the Realm of Centrally-Administered State-Owned Enterprises". Anchored in the strategic imperatives and orientation of such investments amid the unfolding new era, his speech wove through the tapestry of CR Capital's empirical journey in industrial investment. Highlighting a significant milestone, he illuminated that CR Capital, since its inception, has vigorously championed over 110 projects within the domain of strategic emerging industries. This robust portfolio signifies an impressive 70% of CR Capital’s historical investment endeavors. He conveyed CR Capital's commitment to harmonizing China's requirements, corporate potential, and its own forte. This commitment crystallizes in the strategic vision of deploying the "CR Group's Direct Investment Platform for Strategic Emerging Industries + Group's Industrial Fund Operation and Management Platform". This involves an assertive foray into the investment and strategic planning within pivotal sectors like integrated circuits, biotechnology, new materials, and new energy. Such endeavors reinforce CR Capital's resolve to fulfill its pivotal role as a frontrunner among centrally-administered state-owned enterprises.
Highlight of the conference was the collaborative initiative spearheaded by CR Capital, alongside premier entities like the National Innovation Center for Advanced Medical Devices, the Brain Cognition and Brain Disease Institute of the Shenzhen Institute of Advanced Technology, CAS, Shenzhen Institute for Drug Control, FOSUN PHARMA, and the Research Center for Sci-Tech and Finance, Tsinghua PBCSF. Together, they unveiled the “Shenzhen Angel Investment Fund Biopharmaceutical and Healthcare Industries Incubation Program”. This concerted effort marks a significant stride towards catalyzing the accelerated growth of the industry.
